{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-051028","form_type":"8-K","ticker":"ADVB","cik":"0001941029","company_name":"Advanced Biomed Inc.","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.303621+00:00","generated_at":"2026-05-15T00:23:10.146600+00:00","sec_items":["2.01","3.02","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Advanced Biomed completes AI pivot with acquisition of Acellent Technologies","bullets":["Acquired 100% of Acellent Technologies (HK) for 270,000 shares at $4/share, valued at $1.08M; closed April 30, 2026.","Strategic pivot from life sciences to AI development; CEO Yi Lu mutually separated, receives 39,999 shares as severance.","Xiaomin Chen appointed CEO, director, and chairman effective April 28; he has 20+ years AI experience including Google.","Chen's base salary set at $12,000/month; eligible for bonuses and equity incentives.","Chen is the sole shareholder of the acquired entity, creating a direct material interest in the transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-051028","json":"https://secwatch.observer/filing/0001213900-26-051028.json","markdown":"https://secwatch.observer/filing/0001213900-26-051028.md","text":"https://secwatch.observer/filing/0001213900-26-051028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/ea0288766-8k_advanced.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:23:10.146600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d718019cf36c333d28b028ad1d06a03f59d19a9","claim":"Advanced Biomed Inc. issued 270,000 shares of common stock to Mr. Xiaomin Chen for $1,080,000.","evidence_excerpt":"n aggregate estimated consideration of $1,080,000. The shares was issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and the transaction was completed on April 30, 2026. Item 3.02 Unregistered Sales","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"270,000 shares"},{"label":"Purchaser","value":"Mr. Xiaomin Chen"},{"label":"Consideration","value":"$1,080,000"}],"fact_type":"equity_issuance"},{"claim_id":"b22d915439","claim":"Xiaomin Chen was appointed as Chief Executive Officer, director and Chairman of the Board at Advanced Biomed Inc..","evidence_excerpt":"the Board of Directors appointed Mr. Xiaomin Chen as Chief Executive Officer, director and Chairman of the Board of the Company, effective as of April 28, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, director and Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"f3ec24a373","claim":"Yi Lu departed as Chief Executive Officer, director and Chairman of the Board at Advanced Biomed Inc..","evidence_excerpt":"The Company and Mr. Yi Lu, the Company’s Chief Executive Officer, director and Chairman of the Board, have mutually agreed that a leadership transition is necessary and in the best interests of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"mutually agreed to separate"},{"label":"Role","value":"Chief Executive Officer, director and Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"aed47c871f5fb8075771295c8aa3d982d0e7c350","claim":"Advanced Biomed Inc. completed an acquisition involving Acellent Technologies (Hong Kong) Co. Limited for $1,080,000 (closed 2026-04-30).","evidence_excerpt":"Pursuant to the Share Purchase Agreement, the Company agreed to acquire 100% of the equity interest in the Target in exchange for the issuance of 270,000 shares of the Company’s common stock, par value $0.001 per share, valued at $4.00 per share, for an aggregate estimated consideration of $1,080,000. The shares was issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and the transaction was completed on April 30, 2026.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Acellent Technologies (Hong Kong) Co. Limited"},{"label":"Consideration","value":"$1,080,000"},{"label":"Closing","value":"2026-04-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}